Department of Neuroscience and Experimental Therapeutics, College of Medicine, Texas A&M Health Science Center College Station, TX, USA.
Front Endocrinol (Lausanne). 2011 Oct 5;2:38. doi: 10.3389/fendo.2011.00038. eCollection 2011.
This review highlights the role of major endogenous neurosteroids in seizure disorders and the promise of neurosteroid replacement therapy in epilepsy. Neurosteroids are endogenous modulators of seizure susceptibility. Neurosteroids such as allopregnanolone (3α-hydroxy-5α-pregnane-20-one) and allotetrahydrodeoxycorticosterone (3α,21-dihydroxy-5α-pregnan-20-one) are positive modulators of GABA-A receptors. Aside from peripheral tissues, neurosteroids are synthesized within the brain, mostly in principal neurons. Neurosteroids potentiate synaptic GABA-A receptor function and also activate δ-subunit-containing extrasynaptic GABA-A receptors that mediate tonic currents and thus may play an important role in neuronal network excitability and seizure susceptibility. Our studies over the past decade have shown that neurosteroids are broad-spectrum anticonvulsants and confer seizure protection in various animal models. They protect against seizures induced by GABA-A receptor antagonists, 6-Hz model, pilocarpine-induced limbic seizures, and seizures in kindled animals. Unlike benzodiazepines, tolerance does not occur to their actions during chronic administration. Our recent studies provide compelling evidence that neurosteroids may have antiepileptogenic properties. There is emerging evidence that endogenous neurosteroids may play a key role in the pathophysiology of catamenial epilepsy, stress-sensitive seizure conditions, temporal lobe epilepsy, and alcohol-withdrawal seizures. It is suggested that neurosteroid replacement with natural or synthetic neurosteroids may be useful in the treatment of epilepsy. Synthetic analogs of neurosteroids that are devoid of hormonal side effects show promise in the treatment of diverse seizure disorders. Agents that stimulate endogenous production of neurosteroids may also be useful for treatment of epilepsy.
这篇综述强调了内源性神经甾体在癫痫发作障碍中的作用,以及神经甾体替代疗法在癫痫中的应用前景。神经甾体是癫痫易感性的内源性调节剂。神经甾体,如别孕烯醇酮(3α-羟基-5α-孕烷-20-酮)和别四氢脱氧皮质酮(3α,21-二羟基-5α-孕烷-20-酮),是 GABA-A 受体的正变构调节剂。除了外周组织,神经甾体也在大脑内合成,主要在主神经元中合成。神经甾体增强突触 GABA-A 受体功能,还激活含有 δ 亚基的 extrasynaptic GABA-A 受体,介导紧张性电流,因此可能在神经元网络兴奋性和癫痫易感性中发挥重要作用。我们过去十年的研究表明,神经甾体是广谱抗惊厥药,可在各种动物模型中提供抗惊厥保护。它们可预防 GABA-A 受体拮抗剂、6-Hz 模型、毛果芸香碱诱导的边缘性癫痫发作和点燃动物的癫痫发作。与苯二氮䓬类药物不同,在慢性给药期间不会产生对其作用的耐受性。我们最近的研究提供了令人信服的证据,表明神经甾体可能具有抗癫痫发生的特性。越来越多的证据表明,内源性神经甾体可能在月经性癫痫、应激敏感癫痫发作、颞叶癫痫和酒精戒断性癫痫发作的病理生理学中发挥关键作用。有人提出,用天然或合成神经甾体进行神经甾体替代治疗可能对癫痫治疗有用。缺乏激素副作用的神经甾体合成类似物在治疗各种癫痫发作障碍方面显示出前景。刺激内源性神经甾体产生的药物也可能对癫痫治疗有用。